Chimera Investment Corporation (CIM)
NYSE: CIM · IEX Real-Time Price · USD
4.275
+0.025 (0.59%)
May 2, 2024, 1:17 PM EDT - Market open
Chimera Investment Revenue
In the year 2023, Chimera Investment had annual revenue of $252.64M, a decrease of -167.36%. Revenue in the quarter ending December 31, 2023 was $56.01M, a -60.58% decrease year-over-year.
Revenue (ttm)
$252.64M
Revenue Growth
-167.36%
P/S Ratio
4.06
Revenue / Employee
$6,477,897
Employees
39
Market Cap
1.03B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 252.64M | 627.70M | -167.36% |
Dec 31, 2022 | -375.07M | -1.19B | -146.30% |
Dec 31, 2021 | 810.07M | 598.00M | 282.00% |
Dec 31, 2020 | 212.06M | -329.19M | -60.82% |
Dec 31, 2019 | 541.25M | -430.00K | -0.08% |
Dec 31, 2018 | 541.68M | -155.78M | -22.34% |
Dec 31, 2017 | 697.46M | -5.58M | -0.79% |
Dec 31, 2016 | 703.03M | 291.84M | 70.97% |
Dec 31, 2015 | 411.19M | -297.16M | -41.95% |
Dec 31, 2014 | 708.35M | 266.40M | 60.28% |
Dec 31, 2013 | 441.95M | -77.23M | -14.88% |
Dec 31, 2012 | 519.19M | -40.38M | -7.22% |
Dec 31, 2011 | 559.57M | 124.51M | 28.62% |
Dec 31, 2010 | 435.05M | 60.62M | 16.19% |
Dec 31, 2009 | 374.44M | 480.21M | -454.01% |
Dec 31, 2008 | -105.77M | -104.69M | 9,702.60% |
Dec 31, 2007 | -1.08M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Service Properties Trust | 1.87B |
Paramount Group | 743.19M |
Ellington Financial | 276.92M |
Centerspace | 257.92M |
Franklin BSP Realty Trust | 255.13M |
MFA Financial | 248.45M |
Alexander's | 224.96M |
UMH Properties | 220.93M |
CIM News
- 1 day ago - Avilar Therapeutics to Present Preclinical Data for MTAC (M6PR Targeting Chimera) Extracellular Protein Degrader Platform at the American Association of Immunologists Annual Meeting - Business Wire
- 7 days ago - Chimera Investment Corporation Announces Date of First Quarter 2024 Financial Results and Conference Call - Business Wire
- 4 weeks ago - Chimera Declares First Quarter 2024 Common Stock Dividends - Business Wire
- 2 months ago - Chimera Declares First Quarter 2024 Preferred Stock Dividends - Business Wire
- 2 months ago - CHIMERA INVESTMENT CORPORATION REPORTS 4TH QUARTER 2023 EARNINGS - Business Wire
- 3 months ago - Chimera Investment Corporation Announces Date of Fourth Quarter and Full Year 2023 Financial Results and Conference Call - Business Wire
- 5 months ago - KBW Announces Index Rebalancing for Fourth-Quarter 2023 - GlobeNewsWire
- 6 months ago - A Shocking Small-Cap Portfolio That Yields 12% - Forbes